Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
| Image |  |
|---|---|
| Description | scientific article published on 14 November 2016 |
| Author/s | |
| Publication date | November 14, 2016 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |